Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mitazalimab in advanced solid tumors
NCT02829099Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2016
- Primary completion
- Jul 2021
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of mitazalimab in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), pancreatic cancer (PC) and 1 more, sponsored by Janssen Pharmaceutical. Primary endpoints: Incidence of dose-limiting toxicities at 28 days and Incidence of adverse events at 29 months. Started Sep 2016; status: completed.
02
Drugs
mitazalimab
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)pancreatic cancer (PC)cutaneous melanoma (CM)
Beyond the preview
Go deeper on NCT02829099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02829099.